Evidence map›Paper›PMID 40597612›Full record

ArticleBMC microbiology2025

Sputum microbiota profiles of patients with rifampicin-resistant tuberculosis during the intensive-phase treatment.

Xingshan Cai, Yuan Lin, Bitong Wu, Yang Luo, Kun Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xingshan CaiDepartment of Medical Laboratory, State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Guangzhou Chest Hospital, Institute of Tuberculosis, Guangzhou Medical University, Guangdong, 510095, P.R. China.
Yuan LinDepartment of Tuberculosis Internal Medicine, State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Guangzhou Chest Hospital, Institute of Tuberculosis, Guangzhou Medical University, Guangdong, 510095, P.R. China.
Bitong WuDepartment of Tuberculosis Internal Medicine, State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Guangzhou Chest Hospital, Institute of Tuberculosis, Guangzhou Medical University, Guangdong, 510095, P.R. China.
Yang LuoDepartment of Medical Laboratory, State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Guangzhou Chest Hospital, Institute of Tuberculosis, Guangzhou Medical University, Guangdong, 510095, P.R. China.
Kun LiDepartment of Medical Laboratory, State Key Laboratory of Respiratory Disease, Guangzhou Key Laboratory of Tuberculosis Research, Guangzhou Chest Hospital, Institute of Tuberculosis, Guangzhou Medical University, Guangdong, 510095, P.R. China. 489601028@qq.com.

Funding

Guangdong Provincial Health Commission Funding Project A2019342Guangzhou Municipal Health Commission Funding Project 20221A011046Guangzhou Science and Technology Bureau Municipal-University (Institute) Joint Funding Project 2024A03J0585
6 · The paper itself

Abstract

backgroundThe respiratory microbiome plays a crucial role in respiratory health and influences the onset and progression of tuberculosis (TB). However, changes in the respiratory microbiota of patients with rifampicin-resistant TB (RR-TB) during the intensive-phase treatment have not been assessed. This study aimed to investigate the impact of a six-month intensive-phase treatment of second-line anti-TB drugs on the respiratory microbiota of RR-TB patients.

methodsSputum samples were collected from 14 RR-TB patients and 14 healthy controls. Microbiota composition was analyzed using 16S rRNA gene sequencing, and functional predictions were performed to assess metabolic pathway changes.

resultsRR-TB patients exhibited significantly lower alpha diversity compared to healthy controls, but no significant changes were observed after six months of treatment. Beta diversity analysis revealed distinct clustering patterns between RR-TB patients and healthy controls, with no significant differences between pre- and post-treatment groups. Functional analysis showed reduced microbial functions related to pyruvate fermentation and amino acid metabolism in RR-TB patients.

conclusionsThese findings highlight the specific effects of second-line anti-TB drugs on the respiratory microbiota and suggest potential roles of respiratory ecological imbalance in RR-TB pathogenesis. Future studies could explore microbiome-based diagnostic and therapeutic strategies for RR-TB.

Indexed as

Antitubercular AgentsBacteriaMicrobiotaRifampinSputumTuberculosis, Multidrug-ResistantAdultDrug Resistance, BacterialFemaleHumansMaleMiddle AgedMycobacterium tuberculosisRNA, Ribosomal, 16SSequence Analysis, DNATuberculosis, PulmonaryAntitubercular AgentsRifampinRNA, Ribosomal, 16S16S rRNA gene sequencingRifampicin-resistant tuberculosisSputum microbiota

Identifiers

PMID40597612
PMCPMC12220151

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.